Elizabeth Brickley
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 54 | 2025 | 165 | 11.200 |
Why?
| | Zika Virus | 42 | 2025 | 128 | 7.890 |
Why?
| | Microcephaly | 32 | 2025 | 100 | 4.800 |
Why?
| | Pregnancy Complications, Infectious | 29 | 2025 | 406 | 3.620 |
Why?
| | Poliomyelitis | 9 | 2025 | 37 | 2.910 |
Why?
| | Brazil | 56 | 2025 | 169 | 2.770 |
Why?
| | Poliovirus Vaccine, Oral | 6 | 2025 | 25 | 2.250 |
Why?
| | Poliovirus Vaccine, Inactivated | 6 | 2024 | 28 | 2.100 |
Why?
| | Poliovirus | 6 | 2025 | 85 | 2.000 |
Why?
| | Dengue | 4 | 2025 | 83 | 1.550 |
Why?
| | Arboviruses | 2 | 2022 | 14 | 1.510 |
Why?
| | Antibodies, Viral | 10 | 2025 | 652 | 1.500 |
Why?
| | Leprosy | 8 | 2025 | 25 | 1.370 |
Why?
| | Immunity, Mucosal | 7 | 2025 | 96 | 1.310 |
Why?
| | Malaria | 5 | 2019 | 66 | 1.270 |
Why?
| | Epidemics | 4 | 2021 | 92 | 1.110 |
Why?
| | Prenatal Exposure Delayed Effects | 11 | 2025 | 656 | 1.100 |
Why?
| | Anemia | 4 | 2019 | 176 | 1.070 |
Why?
| | Immunoglobulin A | 8 | 2025 | 214 | 1.020 |
Why?
| | Infant | 45 | 2025 | 9790 | 0.970 |
Why?
| | Pregnancy | 44 | 2025 | 7035 | 0.910 |
Why?
| | Antibodies, Neutralizing | 9 | 2025 | 321 | 0.900 |
Why?
| | Disease Outbreaks | 9 | 2024 | 418 | 0.900 |
Why?
| | Vaccines, Attenuated | 3 | 2022 | 130 | 0.900 |
Why?
| | Chikungunya Fever | 2 | 2024 | 80 | 0.900 |
Why?
| | Fetal Blood | 3 | 2017 | 336 | 0.900 |
Why?
| | Socioeconomic Factors | 14 | 2025 | 1310 | 0.800 |
Why?
| | Cohort Studies | 28 | 2025 | 5789 | 0.790 |
Why?
| | Virus Diseases | 3 | 2021 | 215 | 0.740 |
Why?
| | Chikungunya virus | 2 | 2024 | 82 | 0.740 |
Why?
| | Arbovirus Infections | 1 | 2022 | 20 | 0.730 |
Why?
| | Child, Preschool | 38 | 2025 | 11462 | 0.730 |
Why?
| | Feces | 4 | 2022 | 493 | 0.730 |
Why?
| | Infant, Newborn | 33 | 2025 | 6257 | 0.720 |
Why?
| | Vaccines, Inactivated | 2 | 2019 | 68 | 0.720 |
Why?
| | Mosquito Vectors | 2 | 2022 | 26 | 0.690 |
Why?
| | Humans | 111 | 2025 | 140898 | 0.690 |
Why?
| | Malaria Vaccines | 2 | 2017 | 10 | 0.650 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 41 | 0.640 |
Why?
| | Intestinal Mucosa | 3 | 2025 | 628 | 0.630 |
Why?
| | Female | 75 | 2025 | 75540 | 0.600 |
Why?
| | Workplace | 4 | 2024 | 264 | 0.590 |
Why?
| | Coinfection | 1 | 2020 | 131 | 0.590 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 371 | 0.570 |
Why?
| | Coronavirus Infections | 2 | 2020 | 367 | 0.570 |
Why?
| | Influenza Vaccines | 2 | 2019 | 551 | 0.530 |
Why?
| | Anopheles | 1 | 2016 | 16 | 0.510 |
Why?
| | Malaria, Falciparum | 1 | 2016 | 31 | 0.500 |
Why?
| | Hepcidins | 1 | 2016 | 22 | 0.500 |
Why?
| | Vaccination | 6 | 2024 | 1467 | 0.470 |
Why?
| | Young Adult | 24 | 2025 | 13646 | 0.440 |
Why?
| | Fetal Diseases | 3 | 2021 | 180 | 0.430 |
Why?
| | Iron | 1 | 2016 | 323 | 0.420 |
Why?
| | Adult | 39 | 2025 | 39134 | 0.410 |
Why?
| | Male | 46 | 2025 | 69893 | 0.400 |
Why?
| | Influenza, Human | 1 | 2019 | 625 | 0.390 |
Why?
| | Pandemics | 2 | 2020 | 1643 | 0.380 |
Why?
| | Nervous System Malformations | 2 | 2023 | 43 | 0.370 |
Why?
| | Child | 27 | 2025 | 22313 | 0.360 |
Why?
| | Immunoglobulin G | 6 | 2025 | 897 | 0.360 |
Why?
| | Cross-Sectional Studies | 11 | 2025 | 5645 | 0.360 |
Why?
| | Tuberculosis | 2 | 2025 | 279 | 0.350 |
Why?
| | Leprosy, Multibacillary | 2 | 2021 | 2 | 0.350 |
Why?
| | Fetus | 2 | 2021 | 799 | 0.340 |
Why?
| | Exanthema | 2 | 2023 | 81 | 0.340 |
Why?
| | Cryptorchidism | 2 | 2020 | 16 | 0.330 |
Why?
| | Incidence | 11 | 2025 | 2782 | 0.320 |
Why?
| | Adolescent | 19 | 2025 | 22027 | 0.310 |
Why?
| | Biomarkers | 5 | 2020 | 4175 | 0.300 |
Why?
| | Poliovirus Vaccines | 2 | 2019 | 6 | 0.280 |
Why?
| | Virus Shedding | 4 | 2021 | 47 | 0.270 |
Why?
| | Middle Aged | 21 | 2025 | 34487 | 0.270 |
Why?
| | Prospective Studies | 14 | 2025 | 7749 | 0.260 |
Why?
| | Infant Mortality | 3 | 2024 | 121 | 0.260 |
Why?
| | Maternal Exposure | 2 | 2021 | 201 | 0.260 |
Why?
| | Neurodevelopmental Disorders | 2 | 2020 | 210 | 0.260 |
Why?
| | Parturition | 3 | 2023 | 67 | 0.260 |
Why?
| | Urban Population | 2 | 2020 | 481 | 0.260 |
Why?
| | Pregnancy Outcome | 4 | 2025 | 453 | 0.250 |
Why?
| | Cytokines | 1 | 2014 | 2092 | 0.250 |
Why?
| | Risk Factors | 14 | 2025 | 10430 | 0.250 |
Why?
| | Immunoglobulin M | 4 | 2022 | 287 | 0.240 |
Why?
| | Social Segregation | 1 | 2025 | 3 | 0.240 |
Why?
| | Public Housing | 1 | 2025 | 10 | 0.240 |
Why?
| | Adenoids | 2 | 2024 | 12 | 0.230 |
Why?
| | Risk | 3 | 2020 | 903 | 0.230 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 58 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2021 | 3578 | 0.220 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2025 | 68 | 0.220 |
Why?
| | Pharynx | 1 | 2024 | 61 | 0.220 |
Why?
| | Language Development Disorders | 2 | 2022 | 39 | 0.220 |
Why?
| | Income | 1 | 2025 | 198 | 0.220 |
Why?
| | Cold Temperature | 1 | 2025 | 196 | 0.210 |
Why?
| | Prevalence | 6 | 2023 | 2780 | 0.210 |
Why?
| | Transients and Migrants | 1 | 2023 | 25 | 0.210 |
Why?
| | Hospitalization | 2 | 2025 | 2261 | 0.200 |
Why?
| | Americas | 2 | 2020 | 26 | 0.200 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2025 | 151 | 0.200 |
Why?
| | Bayes Theorem | 2 | 2022 | 415 | 0.200 |
Why?
| | Meta-Analysis as Topic | 2 | 2021 | 166 | 0.200 |
Why?
| | Epilepsies, Partial | 2 | 2023 | 57 | 0.200 |
Why?
| | Racism | 1 | 2025 | 139 | 0.200 |
Why?
| | Mortality | 1 | 2025 | 359 | 0.200 |
Why?
| | Belgium | 1 | 2022 | 12 | 0.190 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 383 | 0.190 |
Why?
| | Smokers | 1 | 2023 | 142 | 0.190 |
Why?
| | Electroencephalography | 2 | 2023 | 518 | 0.190 |
Why?
| | Hot Temperature | 1 | 2025 | 406 | 0.190 |
Why?
| | Viruses, Unclassified | 1 | 2022 | 4 | 0.190 |
Why?
| | Temperature | 1 | 2025 | 669 | 0.190 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2025 | 649 | 0.190 |
Why?
| | Urinary Tract | 1 | 2022 | 50 | 0.180 |
Why?
| | United Kingdom | 2 | 2020 | 319 | 0.180 |
Why?
| | Hospital Records | 1 | 2021 | 10 | 0.180 |
Why?
| | Family Characteristics | 2 | 2020 | 191 | 0.180 |
Why?
| | Nervous System | 1 | 2022 | 68 | 0.180 |
Why?
| | Child Mortality | 1 | 2021 | 16 | 0.180 |
Why?
| | Serogroup | 2 | 2018 | 45 | 0.180 |
Why?
| | Hearing Loss | 1 | 2025 | 234 | 0.180 |
Why?
| | Epilepsy | 2 | 2023 | 347 | 0.180 |
Why?
| | Antibody Formation | 1 | 2022 | 297 | 0.170 |
Why?
| | Orchiopexy | 1 | 2020 | 6 | 0.170 |
Why?
| | Control Groups | 1 | 2020 | 12 | 0.170 |
Why?
| | Public Assistance | 1 | 2020 | 20 | 0.170 |
Why?
| | Epidemiologic Research Design | 1 | 2020 | 28 | 0.170 |
Why?
| | Betacoronavirus | 2 | 2020 | 274 | 0.170 |
Why?
| | Cerebral Palsy | 1 | 2023 | 121 | 0.170 |
Why?
| | Air Pollution | 1 | 2024 | 321 | 0.170 |
Why?
| | Language Development | 1 | 2021 | 68 | 0.170 |
Why?
| | Endocrine System Diseases | 1 | 2020 | 35 | 0.170 |
Why?
| | Motor Skills | 1 | 2021 | 103 | 0.160 |
Why?
| | Pregnancy, Twin | 1 | 2020 | 19 | 0.160 |
Why?
| | Leprostatic Agents | 1 | 2020 | 6 | 0.160 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 73 | 0.160 |
Why?
| | Tanzania | 2 | 2019 | 57 | 0.160 |
Why?
| | Malformations of Cortical Development | 1 | 2020 | 13 | 0.160 |
Why?
| | Viral Vaccines | 1 | 2021 | 107 | 0.160 |
Why?
| | Cross-Cultural Comparison | 1 | 2020 | 85 | 0.160 |
Why?
| | Breast Feeding | 1 | 2024 | 442 | 0.160 |
Why?
| | England | 3 | 2024 | 108 | 0.160 |
Why?
| | Developing Countries | 2 | 2019 | 307 | 0.160 |
Why?
| | Respiratory Sounds | 1 | 2020 | 109 | 0.160 |
Why?
| | Plasmodium | 1 | 2019 | 13 | 0.160 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.160 |
Why?
| | Cesarean Section | 1 | 2021 | 213 | 0.160 |
Why?
| | Receptors, Complement 3b | 1 | 2019 | 82 | 0.160 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2019 | 38 | 0.160 |
Why?
| | Protozoan Proteins | 2 | 2017 | 87 | 0.150 |
Why?
| | Air Pollutants | 1 | 2024 | 429 | 0.150 |
Why?
| | Bangladesh | 1 | 2019 | 55 | 0.150 |
Why?
| | Prenatal Diagnosis | 1 | 2021 | 190 | 0.150 |
Why?
| | Registries | 6 | 2025 | 2143 | 0.150 |
Why?
| | Administration, Intranasal | 1 | 2019 | 91 | 0.150 |
Why?
| | Urbanization | 1 | 2019 | 27 | 0.150 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 46 | 0.150 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2019 | 11 | 0.150 |
Why?
| | Infant, Newborn, Diseases | 1 | 2021 | 113 | 0.150 |
Why?
| | Travel | 1 | 2020 | 136 | 0.150 |
Why?
| | Birth Certificates | 1 | 2019 | 12 | 0.150 |
Why?
| | Intestines | 2 | 2021 | 355 | 0.150 |
Why?
| | Death Certificates | 1 | 2019 | 30 | 0.150 |
Why?
| | Chile | 1 | 2018 | 24 | 0.150 |
Why?
| | Esophageal Neoplasms | 1 | 2022 | 336 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2020 | 151 | 0.140 |
Why?
| | Follow-Up Studies | 7 | 2023 | 5194 | 0.140 |
Why?
| | Comorbidity | 2 | 2020 | 1658 | 0.140 |
Why?
| | Medical Record Linkage | 1 | 2019 | 68 | 0.140 |
Why?
| | Developmental Disabilities | 1 | 2021 | 284 | 0.140 |
Why?
| | Rural Population | 2 | 2021 | 605 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 161 | 0.140 |
Why?
| | Immunoglobulin D | 1 | 2018 | 30 | 0.140 |
Why?
| | Sporozoites | 1 | 2017 | 1 | 0.140 |
Why?
| | Spasms, Infantile | 1 | 2020 | 133 | 0.140 |
Why?
| | Research | 1 | 2021 | 431 | 0.140 |
Why?
| | Plasmodium falciparum | 1 | 2017 | 34 | 0.130 |
Why?
| | Nervous System Diseases | 1 | 2020 | 277 | 0.130 |
Why?
| | Asthma | 2 | 2020 | 1919 | 0.130 |
Why?
| | Rectus Abdominis | 1 | 2017 | 17 | 0.130 |
Why?
| | Patient Participation | 1 | 2021 | 424 | 0.130 |
Why?
| | Gestational Age | 4 | 2022 | 952 | 0.130 |
Why?
| | Milk, Human | 1 | 2019 | 169 | 0.130 |
Why?
| | Databases, Factual | 2 | 2021 | 1441 | 0.130 |
Why?
| | Endothelium | 1 | 2017 | 127 | 0.130 |
Why?
| | Esophageal Motility Disorders | 1 | 2016 | 28 | 0.130 |
Why?
| | Sepsis | 1 | 2023 | 620 | 0.130 |
Why?
| | Free Tissue Flaps | 1 | 2017 | 46 | 0.120 |
Why?
| | Arsenic | 1 | 2017 | 63 | 0.120 |
Why?
| | Esophagitis | 1 | 2016 | 67 | 0.120 |
Why?
| | Smoking | 1 | 2023 | 1573 | 0.120 |
Why?
| | Body Composition | 1 | 2019 | 703 | 0.120 |
Why?
| | Adenocarcinoma | 1 | 2022 | 895 | 0.120 |
Why?
| | Social Determinants of Health | 1 | 2019 | 273 | 0.120 |
Why?
| | Mammaplasty | 1 | 2017 | 119 | 0.110 |
Why?
| | Deficiency Diseases | 1 | 2014 | 10 | 0.110 |
Why?
| | Wasting Syndrome | 1 | 2014 | 12 | 0.110 |
Why?
| | Child Nutrition Disorders | 1 | 2014 | 20 | 0.110 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 44 | 0.110 |
Why?
| | Esophagus | 1 | 2016 | 259 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2023 | 2920 | 0.110 |
Why?
| | Lymphocytes | 1 | 2016 | 394 | 0.110 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 84 | 0.110 |
Why?
| | Erythrocytes | 1 | 2019 | 707 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2017 | 502 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 577 | 0.110 |
Why?
| | Tissue Donors | 1 | 2017 | 405 | 0.100 |
Why?
| | Cognition | 1 | 2021 | 1220 | 0.100 |
Why?
| | Ecuador | 2 | 2024 | 10 | 0.100 |
Why?
| | Interleukins | 1 | 2014 | 250 | 0.100 |
Why?
| | Animals | 5 | 2022 | 37579 | 0.090 |
Why?
| | Cause of Death | 2 | 2025 | 441 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 1031 | 0.090 |
Why?
| | Skin | 1 | 2016 | 764 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2017 | 915 | 0.090 |
Why?
| | Diet | 1 | 2019 | 1269 | 0.090 |
Why?
| | Interferon-gamma | 1 | 2014 | 789 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2016 | 679 | 0.080 |
Why?
| | Occupational Exposure | 2 | 2024 | 346 | 0.080 |
Why?
| | Neuroimaging | 2 | 2023 | 279 | 0.080 |
Why?
| | Growth Disorders | 2 | 2024 | 87 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2022 | 16315 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1241 | 0.080 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2021 | 186 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 2017 | 2003 | 0.070 |
Why?
| | Latin America | 2 | 2020 | 89 | 0.070 |
Why?
| | Cerebral Cortex | 2 | 2023 | 457 | 0.070 |
Why?
| | RNA, Viral | 2 | 2023 | 691 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2020 | 1052 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2025 | 11125 | 0.060 |
Why?
| | Spatial Analysis | 1 | 2025 | 21 | 0.060 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2025 | 3 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2025 | 75 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5931 | 0.060 |
Why?
| | Aged | 4 | 2025 | 24666 | 0.060 |
Why?
| | Serum | 1 | 2025 | 58 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2017 | 2813 | 0.060 |
Why?
| | Ventilation | 1 | 2024 | 44 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2024 | 111 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 2967 | 0.050 |
Why?
| | Contact Tracing | 1 | 2023 | 24 | 0.050 |
Why?
| | Manufacturing and Industrial Facilities | 1 | 2023 | 2 | 0.050 |
Why?
| | Alpha Rhythm | 1 | 2023 | 11 | 0.050 |
Why?
| | Theta Rhythm | 1 | 2023 | 15 | 0.050 |
Why?
| | Health Status Indicators | 1 | 2024 | 161 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 577 | 0.050 |
Why?
| | Plastics | 1 | 2023 | 50 | 0.050 |
Why?
| | Sleep Stages | 1 | 2023 | 75 | 0.050 |
Why?
| | Information Storage and Retrieval | 1 | 2023 | 118 | 0.050 |
Why?
| | Eye Movements | 1 | 2023 | 87 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2022 | 34 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 120 | 0.050 |
Why?
| | DNA Viruses | 1 | 2022 | 23 | 0.050 |
Why?
| | Urodynamics | 1 | 2022 | 49 | 0.050 |
Why?
| | Wakefulness | 1 | 2023 | 170 | 0.040 |
Why?
| | Particulate Matter | 1 | 2024 | 330 | 0.040 |
Why?
| | Esophagectomy | 1 | 2022 | 137 | 0.040 |
Why?
| | Age of Onset | 1 | 2023 | 533 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 123 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2022 | 179 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 241 | 0.040 |
Why?
| | Parity | 1 | 2021 | 110 | 0.040 |
Why?
| | Population Groups | 1 | 2021 | 58 | 0.040 |
Why?
| | Lithuania | 1 | 2021 | 1 | 0.040 |
Why?
| | Diagnostic Techniques, Surgical | 1 | 2020 | 2 | 0.040 |
Why?
| | Caribbean Region | 1 | 2020 | 27 | 0.040 |
Why?
| | Testicular Diseases | 1 | 2020 | 7 | 0.040 |
Why?
| | Pregnancy, High-Risk | 1 | 2020 | 15 | 0.040 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 33 | 0.040 |
Why?
| | Infection Control | 1 | 2022 | 165 | 0.040 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 36 | 0.040 |
Why?
| | World Health Organization | 1 | 2020 | 103 | 0.040 |
Why?
| | Hypertrophy | 1 | 2021 | 134 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 83 | 0.040 |
Why?
| | Fetal Death | 1 | 2020 | 59 | 0.040 |
Why?
| | Delivery, Obstetric | 1 | 2021 | 162 | 0.040 |
Why?
| | Maternal Age | 1 | 2020 | 128 | 0.040 |
Why?
| | Causality | 1 | 2020 | 131 | 0.040 |
Why?
| | Treatment Adherence and Compliance | 1 | 2020 | 27 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2019 | 69 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 423 | 0.040 |
Why?
| | Neutralization Tests | 1 | 2019 | 81 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 130 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 271 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2020 | 145 | 0.040 |
Why?
| | Cross Reactions | 1 | 2019 | 133 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 439 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 189 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 907 | 0.040 |
Why?
| | Maternal Death | 1 | 2019 | 14 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 496 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1259 | 0.040 |
Why?
| | Cities | 1 | 2019 | 134 | 0.040 |
Why?
| | Live Birth | 1 | 2019 | 68 | 0.040 |
Why?
| | Maternal Mortality | 1 | 2019 | 52 | 0.040 |
Why?
| | Mosquito Control | 1 | 2019 | 28 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1598 | 0.040 |
Why?
| | Educational Status | 1 | 2021 | 462 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 511 | 0.040 |
Why?
| | Uterus | 1 | 2020 | 220 | 0.040 |
Why?
| | Stillbirth | 1 | 2019 | 74 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 381 | 0.040 |
Why?
| | Species Specificity | 1 | 2019 | 577 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 2019 | 273 | 0.040 |
Why?
| | Capacity Building | 1 | 2019 | 59 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 1054 | 0.040 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 282 | 0.030 |
Why?
| | Mali | 1 | 2017 | 3 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 2020 | 291 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2019 | 105 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2020 | 223 | 0.030 |
Why?
| | Antibodies, Protozoan | 1 | 2017 | 39 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2017 | 76 | 0.030 |
Why?
| | New Hampshire | 1 | 2017 | 6 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 101 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 851 | 0.030 |
Why?
| | United States | 2 | 2025 | 15195 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2891 | 0.030 |
Why?
| | Immunity | 1 | 2017 | 139 | 0.030 |
Why?
| | Prenatal Care | 1 | 2019 | 301 | 0.030 |
Why?
| | Biomedical Research | 1 | 2023 | 680 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2016 | 167 | 0.030 |
Why?
| | Mastectomy | 1 | 2017 | 152 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 992 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 479 | 0.030 |
Why?
| | Immunization Schedule | 1 | 2016 | 202 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2014 | 45 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 501 | 0.030 |
Why?
| | Mothers | 1 | 2020 | 777 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 117 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2017 | 698 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1038 | 0.030 |
Why?
| | Placenta | 1 | 2020 | 764 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 1525 | 0.030 |
Why?
| | Biopsy | 1 | 2016 | 1069 | 0.020 |
Why?
| | Research Design | 1 | 2019 | 1104 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3278 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1763 | 0.020 |
Why?
| | Mass Screening | 1 | 2020 | 1300 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2088 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1020 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2374 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2497 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4199 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2760 | 0.020 |
Why?
| | Liver | 1 | 2017 | 1815 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2791 | 0.020 |
Why?
| | Home Care Services | 1 | 1971 | 260 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3724 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4407 | 0.020 |
Why?
| | Medicare | 1 | 1971 | 806 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18057 | 0.010 |
Why?
| | Nebraska | 1 | 1971 | 19 | 0.010 |
Why?
|
|
Brickley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|